237 million people globally suffer from Macular Degeneration (MD), which is the leading cause of sight loss in the developed world. MD affects 1.6M people in the UK and uses 5% of the NHS’ outpatient appointments. In the next 10 years, 2.3M patients will be affected in the UK.
For a patient with MD, the current care comprises regular appointments with an ophthalmologist and an average of eight eye injections per annum over their lifetime.
Macusoft provides personalised treatment plans for people with Macular Degeneration using existing diagnostic imaging and clinical data. It can work from any care setting, including out-of-hospital health facilities. This improves access for patients and creates much-needed capacity for health systems while reducing cases of sight loss.
- 20% reduction in the number of appointments for macular diseases
- 59% reduction in diagnostic costs, amounting to £2.7M or 27% for the average NHS trust
- Improved access and capacity of outpatient appointments, enabling 2.4M more patients to be seen
- Macusoft’s MacuSense product is currently being trialled in Guy’s and St Thomas’ NHS Foundation Trust